Features | Partner Sites | Information | LinkXpress
Sign In
Ampronix
Schiller
Fluke Biomedical

Pill Colors Play a Role in Medication Adherence

By HospiMedica International staff writers
Posted on 17 Jan 2013
Changes in pill color increase the risk that patients will not complete their antiepileptic drug (AED) prescriptions, according to a new study.

Researchers at Brigham and Women's Hospital (Boston, MA, USA) designed a nested case-control study involving 11,472 patients who failed to refill a prescription for an AED within 5 days of the time they ran out of pills; the controls, 50,050 patients, had no refill delays and were matched to cases by sex, age, number of refills, and the presence of a seizure disorder diagnosis. The researchers evaluated the two refills preceding nonpersistence, and compared the odds of discordance among cases and controls. In all, the drugs dispensed had 37 colors and four shapes.

The researchers found that color discordance preceded 136 cases (1.2%) but only 480 controls (0.97%); shape discordance preceded 18 cases (0.16%) and 54 controls (0.11%). Within a seizure disorder-diagnosis subgroup, the risk of nonpersistence after changes in pill color was also significantly elevated. The researchers concluded that changes in pill color significantly increase the odds of nonpersistence, and urge a reconsideration of current regulatory policy that permits wide variation in the appearance of bioequivalent drugs. The study was published on December 31, 2012, in Archives of Internal Medicine.

“A patient taking five medicines, each produced by five generic manufacturers, theoretically faces over 3,000 possible arrays of pill appearances for what are, chemically and clinically speaking, the same drugs,” said lead author Aaron Kesselheim, MD, JD. “Those choices could confuse patients and result in poor adherence to therapy.”

“Subjecting patients to this risk is absolutely senseless and absurd. Generic medicines should be required to look like their brand-name counterparts,” commented Archives of Internal Medicine associate Editor Kenneth Covinsky, MD. “With all the hurdles patients face, how on earth can we justify confusing them by needlessly changing the appearance of their medicines?”

Related Links:
Brigham and Women's Hospital


MinXray
Bovie Medical
Centurion Service

Channels

Critical Care

view channel
Image: The Trellis peripheral infusion system (Photo courtesy of Covidien).

Thrombolytic Drug Delivery Device Dissolves Blood Clots

A redesigned peripheral infusion system enables focused treatment of blood clots to avoid potential post-thrombotic syndrome (PTS). The updated Trellis peripheral infusion system is a pharmacomechanical... Read more

Surgical Techniques

view channel

Robot-Assisted Technique Improves Small Kidney Tumor Removal

A new study demonstrates that retroperitoneoscopic partial nephrectomy (RARPN) is preferable for excising posterior kidney tumors less accessible through traditional minimally invasive surgery (MIS) approaches. Researchers at the University of California, Los Angeles (UCLA; USA), the Swedish Medical Center (Seattle,... Read more

Women's Health

view channel
Image: A prototype contraceptive implant (Photo courtesy of MicroCHIPS).

Contraceptive Implant Hails New Era of Birth Control

A fingernail-sized implant holds enough 30-microgram daily doses of levonorgestrel to provide contraception for 16 years. Developed by MicroCHIPS (Lexington, MA, USA), a MIT (Cambridge, MA, USA) startup,... Read more

Health IT

view channel
Image: The Health eResearch Center UV2 supercomputer (Photo courtesy of HeRC).

Supercomputer Accelerates Pace of Health Research

The University of Manchester (United Kingdom) is financing a new supercomputer system that can analyze bigger and more complex sets of information. The Health eResearch Center (HeRC; Manchester, United... Read more

Business

view channel

Spectranetics Completes Acquisition of AngioScore

Spectranetics (Colorado Springs, CO, USA) has completed the acquisition of AngioScore (Fremont, CA, USA), a leading developer, manufacturer, and marketer of cardiovascular specialty balloons. The transaction, for USD 230 million in cash and contingent commercial and regulatory milestone payments, will combine differentiated,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.